Tau Oligomers in Sera of Patients with Alzheimer’s Disease and Aged Controls
Abstract
Although tau protein was long regarded as an intracellular protein with several functions inside the cell, new evidence has shown tau secretion into the extracellular space. The active secretion of tau could be a physiological response of neurons to increased intracellular amounts of tau during the progression of tau pathology. We looked for potential differences in the serum levels of toxic tau oligomers in regards to cognitive impairment of subjects. We detected tau oligomers in the serum of Alzheimer’s disease (AD) patients, but they were also present to some extent in the serum of healthy older subjects where the levels positively correlated with aging (Spearman r = 0.26, p = 0.016). On the contrary, we found lower levels of tau oligomers in the serum of mild cognitive impairment (MCI) ( p = 0.033) and MCI-AD ( p = 0.006) patients. These results could suggest that clearance of extracellular tau proteins takes place, in part, in the periphery. In the case of MCI patients, the lower levels of tau oligomers could be the result of impaired clearance of tau protein from interstitium to blood and consequent accumulation of tau aggregates in the brain.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Elevation of SASP components in AD patients correlates with CSF tau levels, inflammation, and cognitive impairment.
“This elevation of SASP components in AD patients correlates with CSF tau levels, inflammation, and cognitive impairment.”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [17]
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · see citing works
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208 · see citing works
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014 · see citing works
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678 · see citing works
Impairment of Glymphatic Pathway Function Promotes Tau Pathology after Traumatic Brain Injury
Iliff, J. J., Chen, M. J., Plog, B. A., Zeppenfeld, D. M., Soltero, M., Yang, L., Singh, I., Deane, R., & Nedergaard, M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3020-14.2014 · Cited by 1,159 · see citing works
Tauopathy in <i>Drosophila</i> : Neurodegeneration Without Neurofibrillary Tangles
Wittmann, C. W., Wszolek, M. F., Shulman, J. M., Salvaterra, P. M., Lewis, J., Hutton, M., & Feany, M. B. (2001) · Science · doi:10.1126/science.1062382 · Cited by 939 · see citing works
Physiological release of endogenous tau is stimulated by neuronal activity
Pooler, A. M., Phillips, E. C., Lau, D. H. W., Noble, W., & Hanger, D. P. (2013) · The EMBO Reports · doi:10.1038/embor.2013.15 · Cited by 642 · see citing works
Neuronal activity regulates extracellular tau in vivo
Yamada, K., Holth, J. K., Liao, F., Stewart, F. R., Mahan, T. E., Jiang, H., Cirrito, J. R., Patel, T. K., Hochgräfe, K., Mandelkow, E., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131685 · Cited by 574 · see citing works
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease
Lasagna‐Reeves, C. A., Castillo‐Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., & Kayed, R. (2012) · The FASEB Journal · doi:10.1096/fj.11-199851 · Cited by 527 · see citing works
Self-citationAccumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy
Berger, Z., Roder, H. M., Hanna, A., Carlson, A. M., Rangachari, V., Yue, M., Wszołek, Z. K., Ashe, K. H., Knight, J. A., Dickson, D. W., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0587-07.2007 · Cited by 485 · see citing works
The molecular bases of Alzheimer’s disease and other neurodegenerative disorders
Maccioni, R. B., Muñoz, J. P., & Barbeito, L. (2001) · Archives of Medical Research · doi:10.1016/s0188-4409(01)00316-2 · Cited by 474 · see citing works
Structure and Pathology of Tau Protein in Alzheimer Disease
Kolarova, M., García‐Sierra, F., Bartoš, A., Říčný, J., & Řı́pová, D. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/731526 · Cited by 473 · see citing works
Self-citationLiu, T., Song, T., Zhang, X., Yuan, H., Su, L., Li, W., Xu, J., Liu, S., Chen, L., Chen, T., et al. (2014) · Nature Communications · doi:10.1038/ncomms5686 · Cited by 394 · see citing works
Plasma tau levels in Alzheimer's disease
Zetterberg, H., Wilson, D. H., Andréasson, U., Minthon, L., Blennow, K., Randall, J., & Hansson, O. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt163 · Cited by 385 · see citing works
Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force
Deisenhammer, F., Bartoš, A., Egg, R., Gilhus, N. E., Giovannoni, G., Rauer, S., & Sellebjerg, F. T. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01493.x · Cited by 368 · see citing works
Preparation and Characterization of Neurotoxic Tau Oligomers
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Jackson, G. R., & Kayed, R. (2010) · Biochemistry · doi:10.1021/bi1016233 · Cited by 359 · see citing works
Self-citationThe Choroid Plexus‐Cerebrospinal Fluid System: From Development to Aging
Redzic, Z. B., Preston, J. E., Duncan, J. A., Chodobski, A., & Szmydynger‐Chodobska, J. (2005) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(05)71001-2 · Cited by 343 · see citing works
Age-Dependent Impairment of Cognitive and Synaptic Function in the htau Mouse Model of Tau Pathology
Polydoro, M., Acker, C. M., Duff, K., Castillo, P. E., & Davies, P. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1065-09.2009 · Cited by 329 · see citing works
Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278 · see citing works
Self-citationBlood–brain-barriers in aging and in Alzheimer’s disease
Marques, F., Sousa, J. C., Sousa, N., & Palha, J. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-38 · Cited by 273 · see citing works
Constitutive secretion of tau protein by an unconventional mechanism
Chai, X., Dage, J. L., & Citron, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.021 · Cited by 224 · see citing works
Choroid plexus ageing of the brain and Alzheimer s disease
Faure, G. C. (2003) · Frontiers in bioscience · doi:10.2741/1085 · Cited by 203 · see citing works
The choroid plexus in the rise, fall and repair of the brain
Emerich, D. F., Skinner, S. J. M., Borlongan, C. V., Vasconcellos, A. V., & Thanos, C. G. (2005) · BioEssays · doi:10.1002/bies.20193 · Cited by 202 · see citing works
Morphological alterations of the choroid plexus in late-onset Alzheimer’s disease
Sérot, J., Béné, M. C., Foliguet, B., & Faure, G. C. (2000) · Acta Neuropathologica · doi:10.1007/pl00007412 · Cited by 181 · see citing works
Amyloid β Oligomers Disrupt Blood–CSF Barrier Integrity by Activating Matrix Metalloproteinases
Brkić, M., Balusu, S., Wonterghem, E. V., Gorlé, N., Benilova, I., Kremer, A., Hove, I. V., Moons, L., Strooper, B. D., Kanazir, S., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0006-15.2015 · Cited by 179 · see citing works
Rickert, C. H., & Paulus, W. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20010101)52:1 · Cited by 160 · see citing works
Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles
Simón, D., García‐García, E., Royo, F., Falcón‐Pérez, J. M., & Ávila, J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.11.022 · Cited by 156 · see citing works
Neurofibrillary tangles and tau phosphorylation
Brion, J., Anderton, B. H., Authelet, M., Dayanandan, R., Leroy, K., Lovestone, S., Octave, J., Pradier, L., Touchet, N., & Tremp, G. L. (2001) · Biochemical Society Symposia · doi:10.1042/bss0670081 · Cited by 139 · see citing works
The Choroid Plexus Removes β-Amyloid from Brain Cerebrospinal Fluid
Crossgrove, J. S., Li, G. J., & Zheng, W. (2005) · Experimental Biology and Medicine · doi:10.1177/153537020523001011 · Cited by 130 · see citing works
CSF biomarkers for Alzheimer's disease: current utility and potential future use
Holtzman, D. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.003 · Cited by 122 · see citing works
Sérot, J., Zmudka, J., & Jouanny, P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111964 · Cited by 114 · see citing works
Are Tangles as Toxic as They Look?
Spires‐Jones, T. L., Kopeikina, K. J., Koffie, R. M., de Calignon, A., & Hyman, B. T. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9566-7 · Cited by 110 · see citing works
Serum Tau Protein Level as a Marker of Axonal Damage in Acute Ischemic Stroke
Bitsch, A., Horn, C., Kemmling, Y., Seipelt, M., Hellenbrand, U., Stiefel, M., Ciesielczyk, B., Cepek, L., Bahn, E., Ratzka, P., et al. (2002) · European Neurology · doi:10.1159/000047946 · Cited by 102 · see citing works
Human Platelets Tau: A Potential Peripheral Marker for Alzheimer's Disease
Neumann, K., Farias, G. A., Slachevsky, A., Perez, P., & Maccioni, R. B. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101641 · Cited by 95 · see citing works
Unconventional protein secretion: membrane translocation of FGF-2 does not require protein unfolding
Backhaus, R., Zehe, C., Wegehingel, S., Kehlenbach, A., Schwappach, B., & Nickel, W. (2004) · Journal of Cell Science · doi:10.1242/jcs.01027 · Cited by 89 · see citing works
Tau protein as a serum marker of brain damage in mild traumatic brain injury: Preliminary results
Bulut, M., Köksal, Ö., Dogan, S., Bolca, N., Ozguc, H., Korfalı, E., Ilcol, Y. O., & Parlak, M. (2006) · Advances in Therapy · doi:10.1007/bf02850342 · Cited by 82 · see citing works
Krzyzanowska, A., & Carro, E. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00075 · Cited by 82 · see citing works
Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies
A. Lasagna-Reeves, C., L. Castillo-Carranza, D., R. Jackson, G., & Kayed, R. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717177 · Cited by 80 · see citing works
Self-citationHighly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluid
Fritschi, S. K., Langer, F., Kaeser, S. A., Maia, L. F., Portelius, E., Pinotsi, D., Kaminski, C. F., Winkler, D. T., Maetzler, W., Keyvani, K., et al. (2014) · Brain · doi:10.1093/brain/awu255 · Cited by 78 · see citing works
Tau oligomers in cerebrospinal fluid in Alzheimer's disease
Sengupta, U., Portelius, E., Hansson, O., Farmer, K., Castillo‐Carranza, D., Woltjer, R., Zetterberg, H., Galasko, D., Blennow, K., & Kayed, R. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.382 · Cited by 77 · see citing works
Self-citationSaman, S., Lee, N. C. Y., Inoyo, I. E., Jin, J., Li, Z., Doyle, T., McKee, A. C., & Hall, G. F. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132135 · Cited by 69 · see citing works
Natural anticoagulants, aging, and thromboembolism
Sagripanti, A., & Carpi, A. (1998) · Experimental Gerontology · doi:10.1016/s0531-5565(98)00047-3 · Cited by 64 · see citing works
What is the pathological significance of tau oligomers?
Cowan, C. M., Quraishe, S., & Mudher, A. K. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120135 · Cited by 62 · see citing works
Bartoš, A., Fialová, L., Švarcová, J., & Řı́pová, D. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.08.001 · Cited by 57 · see citing works
Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis
Bartoš, A., Fialová, L., Soukupová, J., Kukal, J., Malbohan, I. M., & Piťha, J. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0185-0 · Cited by 55 · see citing works
Platelet Tau Pattern Correlates with Cognitive Status in Alzheimer's Disease
Farias, G. A., Pérez, P., Slachevsky, A., & Maccioni, R. B. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120304 · Cited by 54 · see citing works
Tau is reduced in AD plasma and validation of employed ELISA methods.
Sparks, D. L., Kryscio, R. J., Sabbagh, M. N., Ziolkowski, C. H. J., Lin, Y., Sparks, L. M., Liebsack, C., & Johnson‐Traver, S. (2012) · Europe PMC (PubMed Central) · Cited by 45 · see citing works
Sustained choroid plexus function in human elderly and Alzheimer’s disease patients
Spector, R., & Johanson, C. E. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-28 · Cited by 35 · see citing works
Cerebrospinal fluid biomarkers of Alzheimer’s disease
Sui, X., Liu, J., & Yang, X. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1412-1 · Cited by 17 · see citing works
[The value of new diagnostic techniques in Alzheimer's disease].
Scheltens, P., Weinstein, H. C., & van Gool, W. A. (1992) · PubMed · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Sengupta, U., & Kayed, R. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102270 · Cited by 303 · see citing works
Self-citationGaikwad, S., Senapati, S., Haque, M. A., & Kayed, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13490 · Cited by 117 · see citing works
Self-citationThe Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer′s Disease (AD)
Mroczko, B., Groblewska, M., & Litman‐Zawadzka, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194661 · Cited by 106 · see citing works
Cerebral Hypoperfusion and Other Shared Brain Pathologies in Ischemic Stroke and Alzheimer’s Disease
Dong, S., Maniar, S., Manole, M. D., & Sun, D. (2017) · Translational Stroke Research · doi:10.1007/s12975-017-0570-2 · Cited by 69 · see citing works
Chen, T., Yang, Y., Zhu, S., Lu, Y., Zhu, L., Wang, Y., & Wang, X. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104382 · Cited by 64 · see citing works
Inflammation: major denominator of obesity, Type 2 diabetes and Alzheimer’s disease-like pathology?
Kacířová, M., Zmeškalová, A., Kořínková, L., Železná, B., Kuneš, J., & Maletı́nská, L. (2020) · Clinical Science · doi:10.1042/cs20191313 · Cited by 53 · see citing works
Tau internalization: A complex step in tau propagation
Zhao, J., Wu, H., & Tang, X. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101272 · Cited by 46 · see citing works
The prion-like transmission of tau oligomers via exosomes
Jackson, N. A., Guerrero‐Munoz, M. J., & Castillo‐Carranza, D. L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.974414 · Cited by 44 · see citing works
siRNA drug delivery across the blood–brain barrier in Alzheimer's disease
Sajid, M. I., Sheikh, F. S., Anis, F., Nasim, N., Sumbria, R. K., Nauli, S. M., & Tiwari, R. K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114968 · Cited by 45 · see citing works
Distinct Conformations, Aggregation and Cellular Internalization of Different Tau Strains
Karikari, T. K., Nagel, D. A., Grainger, A. I., Clarke-Bland, C., Crowe, J. A., Hill, E. J., & Moffat, K. G. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00296 · Cited by 39 · see citing works
Jaye, S., Sandau, U. S., & Saugstad, J. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1378576 · Cited by 26 · see citing works
Structure-specific amyloid precipitation in biofluids
Rodrigues, M., Bhattacharjee, P., Brinkmalm, A., Do, D. T., Pearson, C. M., De, S., Ponjavic, A., Varela, J. A., Kulenkampff, K., Baudrexel, I., et al. (2022) · Nature Chemistry · doi:10.1038/s41557-022-00976-3 · Cited by 26 · see citing works
Heterogeneous Tau Oligomers as Molecular Targets for Alzheimer’s Disease and Related Tauopathies
Lo, C. H. (2022) · Biophysica · doi:10.3390/biophysica2040039 · Cited by 24 · see citing works
Heme Oxygenase 1 Induces Tau Oligomer Formation and Synapse Aberrations in Hippocampal Neurons
Si, Z., Wang, X., Zhang, Z., Wang, J., Li, J., Li, J., Li, L., Li, Y., Peng, Y., Sun, C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180451 · Cited by 23 · see citing works
Animal Research for Alzheimer Disease: Failures of Science and Ethics
Pippin, J. J., Cavanaugh, S. E., & Pistollato, F. (2019) · BRILL eBooks · doi:10.1163/9789004391192_021 · Cited by 16 · see citing works
Hromádková, L., & Ovsepian, S. V. (2019) · Journal of Immunology Research · doi:10.1155/2019/7406810 · Cited by 17 · see citing works
Boggs, K. N., Kakalec, P. A., Smith, M. L., Howell, S., & Flinn, J. M. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.09.021 · Cited by 14 · see citing works
Tau Diagnostics and Clinical Studies
Gozes, I., Höglinger, G. U., Quinn, J. P., Hooper, N. M., & Höglund, K. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0983-0 · Cited by 12 · see citing works
Alzheimer’s Disease and Its Possible Evolutionary Origin: Hypothesis
Whitfield, J. F., Rennie, K., & Chakravarthy, B. (2023) · Cells · doi:10.3390/cells12121618 · Cited by 11 · see citing works
McArthur, N., Squire, J. D., Onyeachonam, O. J., Bhatt, N. N., Jerez, C., Holberton, A. L., Tessier, P. M., Wood, L. B., Kayed, R., & Kane, R. S. (2024) · Biomaterials Science · doi:10.1039/d4bm00707g · Cited by 8 · see citing works
Self-citationA glimpse into the structural properties of α‐synuclein oligomers
Santos, J., Pallarès, I., & Ventura, S. (2023) · BioFactors · doi:10.1002/biof.2021 · Cited by 7 · see citing works
Sengupta, U., & Kayed, R. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3629-9_9 · Cited by 7 · see citing works
Self-citationDivergent disruptive effects of soluble recombinant tau assemblies on synaptic plasticity in vivo
Yang, Y., Ondrejčák, T., Hu, N., Klyubin, I. V., & Rowan, M. J. (2025) · Molecular Brain · doi:10.1186/s13041-025-01208-8 · Cited by 5 · see citing works
Rabanal‐Ruiz, Y., Pedrero-Prieto, C. M., Rodríguez, L. S., Flores‐Cuadrado, A., Saiz‐Sánchez, D., Frontiñán-Rubio, J., Úbeda‐Bañón, I., Durán‐Prado, M., Martı́nez-Marcos, A., & Peinado, J. R. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167204 · Cited by 3 · see citing works
Gažová, Z., Bednáriková, Z., Bartoš, A., Klaschka, J., & Krištofiková, Z. (2019) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0319 · Cited by 1 · see citing works
Pathological Tau as a Cause, and Consequence, of Cellular Dysfunction
Meier, S. E. (2019) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2019.368
Rabanal‐Ruiz, Y., Pedrero-Prieto, C. M., Sanchez-Rodriguez, L., Flores‐Cuadrado, A., Saiz‐Sánchez, D., Frontiñán-Rubio, J., Úbeda‐Bañón, I., Durán‐Prado, M., Martı́nez-Marcos, A., & Peinado, J. R. (2023) · Research Square · doi:10.21203/rs.3.rs-3343553/v1
- Authors
- Kolarova, M., Sengupta, U., Bartos, A., Ricny, J., & Kayed, R.
- Affiliations
- Charles University (CZ)
- The University of Texas Medical Branch at Galveston (US)
- National Institute of Mental Health, Klecany, Czech Republic
- Corresponding author
- Kolarova, Michala
- Kayed, Rakez
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-04-28
- Volume
- 58
- Issue
- 2
- Pages
- 471-478
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2608194522
- Cited by
- 27
- References
- 53
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 1 · 2020: 2 · 2019: 6 · 2018: 1 · 2017: 3
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Univerzita Karlova v Praze
- Ministerstvo Školství, Mládeže a Tělovýchovy
- National Institutes of Health
- Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch
- National Institute on Aging (R01AG054025)
- National Institute of Neurological Disorders and Stroke (R01NS094557)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau oligomers, Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Mental Status Schedule, Middle Aged, Peptide Fragments, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
